1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (206) 667-7264,
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Combining a symptoms index with CA 125 to improve detection of ovarian cancer
Article first published online: 25 JUN 2008
DOI: 10.1002/cncr.23577
Copyright © 2008 American Cancer Society
Additional Information
How to Cite
Andersen, M. R., Goff, B. A., Lowe, K. A., Scholler, N., Bergan, L., Dresher, C. W., Paley, P. and Urban, N. (2008), Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer, 113: 484–489. doi: 10.1002/cncr.23577
Publication History
- Issue published online: 18 JUL 2008
- Article first published online: 25 JUN 2008
- Manuscript Accepted: 20 MAR 2008
- Manuscript Revised: 14 MAR 2008
- Manuscript Received: 30 NOV 2007
Funded by
- Marsha Rivkin Center for Ovarian Cancer Research (Seattle, Wash)
- National Institutes of Health/National Cancer Institute. Grant Number: P50 CA83636
- Pacific Ovarian Cancer Research Consortium: Specialized Program of Research Excellence in Ovarian Cancer
REFERENCES
- 1,,,,,. Cancer statistics 2008. CA Cancer J Clin. 2008; 58: 71–96.Direct Link:
- 2,,,. Epithelial ovarian cancer. In: HoskinsWJ,PerezCA,YoungR,BarakatR, et al, eds. Principles and Practice of Gynecologic Oncology.4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 895–987.
- 3,,,. Ovarian carcinoma diagnosis: results of a National Ovarian Cancer Survey. Cancer. 2000; 89: 2068–2075.Direct Link:
- 4,,,. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004; 291: 2705–2712.
- 5,,, et al. Development of an ovarian cancer symptom index. Cancer. 2007; 109: 221–227.Direct Link:
- 6,. Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol. 2001; 13: 61–64.
- 7National Institutes of Health. Consensus Development Conference Statement. Ovarian cancer: screening, treatment and followup, Gynecol Oncol. 1994; 55: S4–S14.
- 8,,, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000; 21( 6 suppl): 273S–309S.
- 9,,, et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet. 1999; 353: 1207–1210.
- 10,,, et al. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol. 2006; 108: 1176–1184.
- 11,,,. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. J Natl Cancer Inst. 1988; 80: 208–209.
- 12,,,,,. Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 1993; 269: 1123–1126.
- 13,,, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005; 23: 7919–7926.
- 14,,, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004; 95: 9–15.
- 15,,, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004; 22: 4059–4066.
- 16,,, et al. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res. 2006; 12: 2117–2124.
- 17,,, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005; 15( suppl 3): 274–281.Direct Link:
- 18,,, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999; 96: 11531–11536.
- 19,,,. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003; 17: 989–1005.
- 20,,, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005; 99: 267–277.
- 21,,, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1014–1020.
- 22,,, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005; 65: 2162–2169.
- 23,,, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003; 63: 3695–3700.
- 24,,, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999; 238: 375–385.
- 25,,,,,. Symptoms of ovarian cancer. Obstet Gynecol. 2001; 98: 212–217.
- 26,,,. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2006; 100: 20–26.
- 27,. The effects of symptoms and delay in seeking diagnosis on stage of disease at diagnosis among women with cancers of the ovary. Cancer. 1985; 56: 2727–2732.Direct Link:
- 28,,,,,. Cancer incidence in a population of Jewish women at risk of ovarian cancer. J Clin Oncol. 2002; 20: 1570–1577.
- 29,,, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005; 192: 1214–1221.